The NAD Dependent Protein Deacetylase Sirtuin 1 pipeline drugs market research report outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the NAD Dependent Protein Deacetylase Sirtuin 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Oncology, Central Nervous System, and Gastrointestinal which include the indications Obesity, Mitochondrial Diseases, Unspecified Cancer, Oncology, Alzheimer’s Disease, Friedreich Ataxia, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It also reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 1 targeted therapeutics development with respective active and dormant or discontinued products.
The NAD Dependent Protein Deacetylase Sirtuin 1 pipeline targets constitutes close to 12 molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 5, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 1 molecule.
NAD Dependent Protein Deacetylase Sirtuin 1 overview
NAD-dependent deacetylase sirtuin-1 is a protein encoded by the SIRT1 gene. It modulates chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. It is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5′-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT).
For a complete picture of NAD Dependent Protein Deacetylase Sirtuin 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
